Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telavancin vs Vancomycin in cSSSI (ATLAS 1)
NCT00091819Phase 3Completed
- Sponsor
- Cumberland Pharmaceuticals
- Start
- Jan 2005
- Primary completion
- Jun 2006
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telavancin in Skin and Skin Structure Infection (SSSI) (2 arms), sponsored by Cumberland Pharmaceuticals. Primary endpoint: Clinical Response at Test-of-Cure. Started Jan 2005; status: completed.
02
Drugs
telavancin
03
Conditions
Skin and Skin Structure Infection (SSSI)
Beyond the preview
Go deeper on NCT00091819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091819.